Ramucirumab
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Adenocarcinoma
Conditions
Pancreatic Adenocarcinoma
Trial Timeline
Jan 29, 2019 → Apr 23, 2023
NCT ID
NCT03745430About Ramucirumab
Ramucirumab is a phase 1/2 stage product being developed by Eli Lilly for Pancreatic Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03745430. Target conditions include Pancreatic Adenocarcinoma.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Adenocarcinoma were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02065765 | Pre-clinical | Completed |
| NCT04557384 | Phase 1 | Terminated |
| NCT03745430 | Phase 1/2 | Completed |
| NCT02564198 | Phase 1 | Completed |
| NCT02443883 | Phase 2 | Completed |
| NCT01983878 | Phase 2 | Completed |
| NCT01682135 | Phase 1 | Completed |
| NCT00721162 | Phase 2 | Completed |
| NCT00515697 | Phase 2 | Completed |
Competing Products
20 competing products in Pancreatic Adenocarcinoma